OBSOLETE: Mycobacterium xenopi infection

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:314946
Who is this for?
Show terms as
1FDA treatments2Active trials8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Mycobacterium xenopi infection is a condition caused by a type of bacteria called Mycobacterium xenopi, which belongs to a group known as nontuberculous mycobacteria (NTM). This organism is found in the environment, particularly in water sources including hot water systems, and can cause lung disease that resembles tuberculosis. The infection most commonly affects the lungs, leading to chronic cough, shortness of breath, fatigue, weight loss, and sometimes fever and night sweats. It tends to occur in people who already have underlying lung conditions such as chronic obstructive pulmonary disease (COPD), prior tuberculosis, or other structural lung damage, as well as in people with weakened immune systems. Note that this entry is marked as 'OBSOLETE' in the Orphanet classification, meaning it may have been reclassified or merged into a broader category of nontuberculous mycobacterial infections. Mycobacterium xenopi infection is not a genetic disease — it is an infectious condition. Treatment typically involves a combination of antibiotics taken over many months, but the infection can be difficult to treat and may recur. The choice of antibiotics and duration of therapy depend on the severity of disease and the patient's overall health. Outcomes vary widely, with some patients responding well to treatment while others experience chronic or progressive disease.

Key symptoms:

Chronic cough that lasts weeks or monthsCoughing up blood or blood-streaked mucusShortness of breathUnexplained weight lossFatigue and low energyFeverNight sweatsChest painLoss of appetiteRecurrent lung infections

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

3 events
Jun 2025Biomarkers of Phage Treatment Response in NTM and Other Infections

NYU Langone Health

TrialRECRUITING
May 2021Hypertonic Saline for MAC

Oregon Health and Science University — PHASE4

TrialRECRUITING
Dec 1992

Mycobutin: FDA approved

Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Mycobutin

Rifabutin· Adria Laboratories, Inc.Orphan Drug

Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.

Clinical Trials

2 recruitingView all trials with filters →
Phase 41 trial
Hypertonic Saline for MAC
Phase 4
Actively Recruiting
· Sites: New York, New York; Portland, Oregon +1 more · Age: 1899 yrs
Other1 trial
Biomarkers of Phage Treatment Response in NTM and Other Infections
Actively Recruiting
PI: Doreen Addrizzo-Harris, MD, FCCP (NYU Langone Health) · Sites: New York, New York · Age: 1899 yrs

No specialists are currently listed for OBSOLETE: Mycobacterium xenopi infection.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Mycobacterium xenopi infection.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Mycobacterium xenopi infectionForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Mycobacterium xenopi infection.

Start the conversation →

Latest news about OBSOLETE: Mycobacterium xenopi infection

No recent news articles for OBSOLETE: Mycobacterium xenopi infection.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which specific antibiotics will I be taking, and for how long?,What side effects should I watch for with my medications?,How often will I need follow-up tests and imaging?,Is my infection likely to respond well to treatment based on drug susceptibility results?,Are there any activities or environments I should avoid?,What are the signs that my treatment is working or not working?,Should I be referred to a specialized NTM treatment center?

Common questions about OBSOLETE: Mycobacterium xenopi infection

What is OBSOLETE: Mycobacterium xenopi infection?

Mycobacterium xenopi infection is a condition caused by a type of bacteria called Mycobacterium xenopi, which belongs to a group known as nontuberculous mycobacteria (NTM). This organism is found in the environment, particularly in water sources including hot water systems, and can cause lung disease that resembles tuberculosis. The infection most commonly affects the lungs, leading to chronic cough, shortness of breath, fatigue, weight loss, and sometimes fever and night sweats. It tends to occur in people who already have underlying lung conditions such as chronic obstructive pulmonary disea

How is OBSOLETE: Mycobacterium xenopi infection inherited?

OBSOLETE: Mycobacterium xenopi infection follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does OBSOLETE: Mycobacterium xenopi infection typically begin?

Typical onset of OBSOLETE: Mycobacterium xenopi infection is adult. Age of onset can vary across affected individuals.

Are there clinical trials for OBSOLETE: Mycobacterium xenopi infection?

Yes — 2 recruiting clinical trials are currently listed for OBSOLETE: Mycobacterium xenopi infection on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

What treatment and support options exist for OBSOLETE: Mycobacterium xenopi infection?

2 patient support programs are currently tracked on UniteRare for OBSOLETE: Mycobacterium xenopi infection. See the treatments and support programs sections for copay assistance, eligibility, and contact details.